Featured
-
-
Article |
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma
The authors report on prospective exploratory analyses of circulating tumour DNA in an urothelial carcinoma immunotherapy clinical trial.
- Thomas Powles
- , Zoe June Assaf
- & Sanjeev Mariathasan
-
Letter |
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
In humans, TGFβ signalling is associated with lack of response to immunotherapy in immune-excluded tumours; in mouse models of this immune phenotype, robust tumour infiltration by T cells and tumour regression are observed only when checkpoint inhibition is combined with inhibition of TGFβ signalling.
- Sanjeev Mariathasan
- , Shannon J. Turley
- & Thomas Powles
-
-
Outlook |
Unlocking bladder cancer
The diagnostics, treatment and five-year survival rates for bladder cancer are largely unchanged since the 1990s. Research into cancer genomics, risk factors and immune therapies could hold the key to progress against this malignant disease.
- Chris Berdik
-
Outlook |
Bladder cancer: 4 big questions
Tackling the challenges of genomics and studies of the immune system should help to create much-needed diagnostics and treatments.
- Chris Berdik
-
Outlook |
Genetics: A clearer view
Researchers delving into the details of bladder cancer are finding a rich trove of genetic information.
- Jeanne Erdmann
-
Outlook |
Egypt: The flatworm's revenge
How Egyptian men swapped one type of bladder cancer for another.
- Louise Sarant
-
Outlook |
Microbiome: A bag of surprises
Once thought to be sterile, the bladder contains microbes that could influence the development and treatment of cancer.
- Claire Ainsworth
-
Outlook |
Theatre: The bladder's tale
What happens when a professor of theatre finds out she has bladder cancer? She writes a one-woman play about it, of course.
- Tammy Worth
-
Outlook |
Perspective: Bridging the gender gap
Bladder cancer is more deadly in women than in men. That needs to change, say James McKiernan and Denise Asafu-Adjei.
- James McKiernan
- & Denise Asafu-Adjei
-
Outlook |
Q&A: Mechele Leon: Take it away
Mechele Leon, an associate professor of theatre at the University of Kansas in Lawrence, was diagnosed with bladder cancer in March 2016. After treatment, Leon was left with no bladder, a urostomy bag, and a story to tell — which became a one-woman play called Bladder Interrupted.
- Tammy Worth
-
Outlook |
Therapeutics: Spoilt for choice
People with metastatic bladder cancer once faced meagre treatment options and a grim prognosis. But immunotherapy has started to yield results.
- Michael Eisenstein
-
Outlook |
Diagnostics: A flow of information
Many non-invasive approaches to detecting bladder cancer are showing promise — including smart toilets.
- Chelsea Wald
-
Letter |
Hedgehog/Wnt feedback supports regenerative proliferation of epithelial stem cells in bladder
The maintenance and regeneration of the epithelium of the adult bladder is poorly understood yet it is a clinically relevant process during urinary tract infections and bladder cancer. This study provides insight into the cellular and molecular mechanisms underlying the regenerative response to injury within the mammalian urinary bladder. Upon injury by bacterial infection or chemical agents, a Shh and Wnt signalling feedback circuit between basal cells of the urothelium and the stromal cells that underlie them leads to regenerative proliferation of the bladder epithelia.
- Kunyoo Shin
- , John Lee
- & Philip A. Beachy
-
Research Highlights |
Cancer biology: Arsenic activation